Skip to main content

Nexstim Plc: Mikko Karvinen appointed as permanent CEO and Joonas Juokslahti as permanent CFO

Written by Customer Service on . Posted in Public Companies.

Company announcement, Helsinki, 16 June 2020, at 7.00 pm EET
Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “the Company”) announces that the Board of Directors has appointed, effective immediately, the current interim CEO Mikko Karvinen (born in 1976) as permanent CEO and the current interim CFO Joonas Juokslahti (born in 1986) as permanent CFO.Mikko Karvinen holds a Master in Science (M.S) and an Executive MBA from Aalto University. Karvinen worked as Nexstim’s CFO between August 2014 and 10 February 2020 and as of 11 February 2020 as the interim CEO. Joonas Juokslahti holds a Master in Science (M.S), and he joined Nexstim in May 2014 as Business Controller and has been a key part of the Nexstim finance team acting first as Finance Manager and since 11 February 2020 as the interim CFO.Leena Niemistö, the Chairman of the Board of Directors, comments as follows: “The Board of Directors of Nexstim wishes to thank Mikko Karvinen and Joonas Juokslahti for their critical contribution in the company’s subscriptions rights issue which ended with excellent results. It is now important – or should I say necessary – to ensure the positive development of the company by making their positions in the management permanent.”NEXSTIM PLCLeena Niemistö, Chair of the Board of DirectorsFurther information is available on the website www.nexstim.com or by contacting:Leena Niemistö, Chair of the Board of Directors
 +358 9 2727 170
leena.niemisto@nexstim.comErik Penser Bank AB (Certified Adviser)                                                                                                                                  
+46 8 463 83 00
certifiedadviser@penser.seAbout Nexstim PlcNexstim is a Finnish medical technology company operating in international markets. Our mission is to enable the individual and efficient diagnosis and treatment of challenging brain diseases and disorders. Nexstim has developed a pioneering non-invasive brain stimulation technology entitled SmartFocus®. SmartFocus® is based on transcranial magnetic stimulation (TMS) combined with a 3D navigation system. The unique technology allows the required area of brain to be stimulated accurately and individually.The SmartFocus® TMS technology is used in NBT® (Navigated Brain Therapy) equipment developed by Nexstim. Marketing and distribution of the equipment for the treatment of serious depression in the USA has been authorised by FDA. NBT® equipment has been CE approved in Europe for the treatment of serious depression and chronic neuropathic pain.Furthermore, Nexstim is marketing the Navigated Brain Stimulation (NBS) equipment, developed by it and based on   SmartFocus® TMS technology. Nexstim’s NBS system is the only FDA cleared and CE marked navigating TMS equipment for the pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden trading facilities.For more information, please visit www.nexstim.comAttachmentNexstim Company Announcement_15062020_CEO and CFO_ENG_FINAL

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.